BRIEF-Gilead presents results from Phase 3 studies By: Reuters: Company News October 24, 2016 at 07:57 AM EDT * Gilead presents results from Phase 3 studies evaluating switching to Descovy (FTC/TAF)-based regimens from Truvada(FTC/TDF)-based regimens Read More >> Related Stocks: Gilead Sciences